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Abstract 
Short Communication on IGF1, with data on 
DNA/RNA, on the protein encoded and where the 
gene is implicated. 
Identity 
Other names: IGF-I, IGF1A, IGFI 
HGNC (Hugo): IGF1 
Location: 12q23.2 
DNA/RNA 
Description 
Genomic size: 84779 bp. The IGF-1 Gene is  
composed of 6 different exons.  
Exons 1 and 2 determine the class of the protein 
and functionally represent the signal peptide for 
cellular localization post-translation.  
Exons 3 and 4 will primarily encode the IGF-1 
mature peptide; ultimately becoming the receptor 
binding ligand.  
Exons 5 and 6 will primarily represent the E 
domain peptide; with exon six providing the 
different polyadenylating signals.  
These parts of the transcript give a functional 
distinction to the 6 isoforms produced (although 
such distinctions have yet to be definitively 
identified) (Adapted from Mills et al., 2007; 
Philippou et al., 2007). 
 
Illustrates IGF-1 splice sites and isoform variants (adapted from Mills et al., 2007). 
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Transcription 
Six different heterogeneous mRNA are transcribed 
using alternate promoters, alternate splice sites and 
varying polyadenylation signals. Class one and two 
are derived from the exon one and two promoter 
respectively; both are differentially spliced to the 
common three exon. Each class can be variably 
spliced to the fifth and sixth exons, producing a 
total of six different isoforms (Philippou et al., 
2007). 
Class one isoforms predominate in the extrahepatic 
tissues and are secreted in a paracrine/autocrine 
fashion. 
Class two isoforms predominate in the liver and are 
secreted in an endocrine fashion. They are also 
more sensitive or responsive to growth hormone 
relative to class 1 (Mills et al., 2007). 
Individual isoforms may be more favorably 
translated depending on the tissue type, the 
available binding proteins and the physiological 
context. 
Researchers are discovering evidence that suggest 
certain isoforms may be preferentially expressed 
under varying amounts of mechanical pressure in 
skeletal muscle (Philippou et al., 2007). The 
advantages of one isoform or another, in varying 
contexts of stress, inflammation, regeneration and 
hypertrophy are yet to be elucidated. 
Pseudogene 
Not reported. 
Protein 
Description 
Single polypeptide chain protein consisting of 70 
amino acids and three disulfide bridges. 
Expression 
It is primarily produced and secreted in endocrine 
fashion by the liver. It is also produced and secreted 
in autocrine or paracrine fashion in a wide range of 
extra-hepatic tissues. Tissues produce IGF-1 protein 
in response to growth hormone during periods of 
pre/post-natal development, exercise and injury. 
Inhibited in undernourished states, low protein, 
growth hormone deficiency and growth hormone 
receptor insensitivity (Cheng et al., 2006). 
Localisation 
The protein is post-translationally modified by 
protease cleavage of the signal and E-peptide. The 
mature protein subsequently binds to one of six 
binding proteins and is then secreted form the tissue 
of origin (IGFBP1, IGFBP2, IGFBP3, IGFBP4, 
IGFBP5, IGFBP6). IGFBP3 predominates, binding 
to 80% of the available IGF-1. The binding proteins 
increase the half life of IGF, preventing renal  
clearance and inactivation. IGFBP (1,3,4,6) are 
growth promoting; IGFBP-(2,5) bind IGF-1 and 
limit IGFR/IGF-1 interaction; a growth inhibiting 
effect. 
Function 
Important for growth/development in children and 
adults. Vital role in anabolic processes in general. 
Important functions in osteogenesis, axonal 
generation in nerves, nerve regeneration after 
ischemic insult, muscle repair and hypertrophy after 
trauma or exercise (Cheng et al., 2006). Although 
still under investigation, studies suggest that 
individual isotype/binding protein combinations 
manifest in response to specific environmental 
interactions or physiological demands. In addition, 
the binding proteins are critical for maintaining the 
bioavailability of the IGF-1. The unique IGF-
1/IGF-1 receptor complex will then signal the 
protein cascade necessary for tissue metabolism or 
regeneration. Ischemic damage to the brain 
illustrates how this concept materializes. Cytotoxic 
edema and inflammatory markers induce the 
transcription of a specific isotype; which then binds 
to a tissue specific binding protein; protecting the 
integrity of the protein and preventing its renal 
clearance. The distinctive IGF-1/IGF-1R complex 
will then activate the protein kinase cascade 
necessary for axonal regeneration.  
Cellular/molecular effects: Upon binding, the 
tyrosine kinase receptor, IGF-1/IGF-1R complex 
activates the PI3K/AKT/mTOR and 
RAS/RAF/MAPK protein cascades. Both interfere 
with apoptosis and are pro-cell survival; the latter 
additionally promotes cellular differentiation, 
metabolism, growth and repair. Given its integral 
utility in tissue growth, repair and cell cycle 
regulation, IGF-1 receptors are found ubiquitously 
throughout the body and include: muscle, bone, 
cartilage, kidney, liver, lung and nervous tissue 
(Schiaffino et al., 2011). 
It is speculated that binding proteins may not only 
enhance or subdue IGF-1/IGF-1R interaction but 
help specify which isoform should predominate. 
Biotech and Clinical Application: Recombinant 
IGF-1 expressed in e. Coli is being tested either for 
symptomatic relief, tissue regeneration or 
penetrance reduction in the following diseases or 
conditions:  
- Laron's Dwarfism 
- Duchenne's Muscular Dystrophy 
- Amyotrophic Lateral Sclerosis 
- Post ischemic damage to brain (stroke)  
- Diabetes and Insulin Insensitivity 
Homology 
Shares some sequence homology to insulin and has 
a relatively weak affinity to insulin receptors. 
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IGF-1 mediated signal transduction (adapted from Schiaffino, S. et. al, 2011). 
 
 
Implicated in 
Various cancers 
Note 
No specific mutations of IGF-1 have been 
connected to genetically acquired diseases. Despite 
this fact, certain haplotypes of IGF-1 have been 
implicated in the survival of solid tumors. It is 
postulated that IGF-1 has tumor promoting effects 
when its cellular growth/anti-apoptotic functions 
become dysregulated (see oncogenesis below). 
Additionally it plays a critical role in the clinical 
sequelae of Laron's dwarfism (see below). 
Disease 
High levels implicated in the survival of solid 
tumors and Acromegaly. Low levels of IGF-
1/IGFBP3 consistently found in Laron's Dwarfism; 
An Autosomal recessive disease caused by a 
mutation in the growth hormone receptor; causing 
poor ligand interaction with growth hormone and 
subsequent low levels of IGF-1. 
Prognosis 
Individuals with Laron's are dwarfs with 
characteristic facial and anatomical anomalies (flat 
nasal bridge, prominent forehead, obesity, small 
mandible and phallus). They also exhibit seizures 
secondary to hypoglycemia. Unlike 
Achondroplasia, Laron's Dwarfism does not 
respond to GH. Laron Dwarfs have a greater 
resistance to diabetes, cancer and age progression; 
underscoring the function of IGF-1 and its critical 
role in cellular metabolism and cell cycle 
maintenance (Melnik et al., 2011). 
Oncogenesis 
IGF-1 signaling through RAS/RAF/MAPK and has 
been demonstrated to promote breast cancer and 
prostate tumorigenesis. IGF-1/IGF-R interaction 
induces the transcription of survival/ growth 
enhancing genes. Signaling through these pathways 
results in increased cellular proliferation and anti-
apoptotic effects; promoting a favorable 
environment for tumor growth.  
In General, high levels of IGF-1 are found in solid 
tumors (particularly breast and prostate). Certain 
SNP's and IGF-1 haplotypes have been associated 
with increased risk of colon, pancreatic, prostate 
and breast cancer.  
It is likely that specific haplotypes in combination 
with other variables can create a more favorable 
tumorigenic environment. i.e. Individuals with a 
BMI>25, containing specific IGF-1 haplotypes may 
have a greater risk of developing pancreatic cancer 
(Cheng et al., 2006). 
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